ClinicalTrials.gg
Status unknownNCT05425602Updated Jun 21, 2022

A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

A Phase 1/2 interventional study of MAX-40279-01: 50mg/70mg in Advanced / Metastatic Solid Tumors, sponsored by Maxinovel Pty., Ltd.. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Maxinovel Pty., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.

Read the detailed description

This study is a study of MAX-40279 in patients with advanced / metastatic solid tumors. This study include two Parts, the Part 1 will assess the safety and efficacy of the dose climbing level of MAX-40279, and recommend a dose extending level of MAX-40279 for stage 2.

02

Conditions studied

  • Advanced / Metastatic Solid Tumors
03

In context

Lead sponsor

Maxinovel Pty., Ltd. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form.
  2. Males and/or females over age 18 and 75.
  3. or cytologically documented local advanced / solid tumors who have failed standard treatment or cannot obtain standard treatment in the dose escalation stage; dose expansion stage group A: advanced gastric cancer; dose expansion stage group B: relapsed and refractory extensive stage small cell lung cancer; dose expansion stage group C: other relapsed and refractory solid tumors except group A
  4. At least one according to the (RECIST 1.1).
  5. (ECOG) performance status of 0-1.
  6. Expected survival of more than 3 months.

Exclusion criteria

Exclusion Criteria:

  1. The adverse reactions of previous anti-tumor treatment have not recovered to 5.0 grade evaluation ≤ 1 (except alopecia and other adverse reactions without safety risks judged by the investigator)
  2. Subject is known to have previous serious allergic reactions to macromolecular protein preparations/monoclonal antibodies, or known to any component of the test drug
  3. Active systemic infectious diseases requiring intravenous antibiotic treatment 2 months before the first medication
  4. Subject has poorly controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited to: such as: (1) class II or higher heart failure or \< 50%; (2) unstable angina pectoris; (3) myocardial infarction and cerebral infarction within 6 months; (4) supraventricular or ventricular arrhythmias are still poorly controlled without clinical intervention or clinical intervention
  5. , spinal cord compression, carcinomatous meningitis with clinical symptoms, or other evidence of uncontrolled brain and spinal cord , Patients who are not suitable by the investigator's judgment
  6. Patients who have experienced ≥ grade 3 immune-related adverse events in immunotherapy (except grade 3 hypothyroidism that can be controlled by drugs)
  7. Patients who have other malignant tumors within 5 years before enrollment,Exceptions: a. radical cervical carcinoma in situ or non-melanoma skin cancer; b. radical second primary cancer without recurrence within five years; c. the investigator believes that the double primary cancer can benefit from this study; d. the investigator has clearly excluded which primary tumor source the metastasis
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    MAX40279-01+KN046

    This is an open-label Phase I/II clinical study. Drug: Stage1: Dose1:MAX40279-01 (35mg BID)+KN046 ( 5mg/kg Q3Week) Drug: Stage1: Dose2:MAX40279-01( 50mg BID)+KN046 ( 5mg/kg Q3Week) Drug: Stage1: Dose3:MAX40279-01( 70mg BID)+KN046 ( 5mg/kg Q3Week) Drug: Stage2: Dose3:MAX40279-01( RP2D BID)+KN046 ( 5mg/kg Q3Week)

    Drug: MAX-40279-01: 50mg/70mg

Interventions

  • DrugMAX-40279-01: 50mg/70mg

    \[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.

    Also known as: KN046: 40mg/300mg

06

What researchers measure

Primary outcomes

  1. DLT

    Time frame: through study Stage1 completion,an average of 6 months

  2. Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)

    Time frame: through study Stage1 completion,an average of 6 months

  3. ORR

    Time frame: through study Stage2 completion,an average of 24 months

  4. PFS

    Time frame: through study Stage2 completion,an average of 24 months

  5. Adverse events (AEs), serious adverse events (SAEs)

    Time frame: through study Stage2 completion,an average of 24 months

  6. laboratory tests

    Time frame: through study Stage2 completion,an average of 24 months

  7. vital signs

    Time frame: through study Stage2 completion,an average of 24 months

  8. 12 ECG

    Time frame: through study Stage2 completion,an average of 24 months

  9. physical examination abnormalities

    Time frame: through study Stage2 completion,an average of 24 months

Secondary outcomes

  1. Adverse events (AEs), serious adverse events (SAEs)

    Time frame: through study Stage1 completion,an average of 6 months

  2. Cmax

    Time frame: through study Stage1 completion,an average of 6 months

  3. Anti-KN046 antibody (ADA

    Time frame: through study Stage1 completion,an average of 6 months

  4. Duration of response (DOR) Overall survival (OS); Anti-KN046 antibody (ADA); Plasma concentrations of MAX-40279 and KN046 [Stage 2]

    Time frame: through study Stage2 completion,an average of 24 months

  5. (AUC0-t and AUC0-t, ss)

    Time frame: through study Stage1 completion,an average of 6 months

  6. Tmax

    Time frame: through study Stage1 completion,an average of 6 months

  7. Overall response rate (ORR)

    Time frame: through study Stage1 completion,an average of 6 months

  8. disease control rate (DCR)

    Time frame: through study Stage1 completion,an average of 6 months

  9. duration of response (DOR)

    Time frame: through study Stage1 completion,an average of 6 months

  10. progression-free survival (PFS)

    Time frame: through study Stage1 completion,an average of 6 months

  11. overall survival (OS)

    Time frame: through study Stage1 completion,an average of 6 months

  12. DcR

    Time frame: through study Stage2 completion,an average of 24 months

  13. DoR

    Time frame: through study Stage2 completion,an average of 24 months

  14. OS

    Time frame: through study Stage2 completion,an average of 24 months

  15. Anti-KN046 antibody (ADA)

    Time frame: through study Stage2 completion,an average of 24 months

  16. Rac (AUC0-t, ss/AUC0-t)

    Time frame: through study Stage1 completion,an average of 6 months

  17. laboratory tests

    Time frame: through study Stage1 completion,an average of 6 months

  18. vital signs

    Time frame: through study Stage1 completion,an average of 6 months

  19. 12 ECG

    Time frame: through study Stage1 completion,an average of 6 months

  20. physical examination abnormalities

    Time frame: through study Stage1 completion,an average of 6 months

Other outcomes

  1. FGFR1OP2-related protein expression levels and mutations, PD-L1 and related inflammatory factors correlate with efficacy [Stage 1]

    Time frame: through study Stage1 completion,an average of 6 months

  2. FGFR1OP2-related protein expression levels and correlation of mutations, PD-L1, tumor mutation burden, and related inflammatory factors with efficacy.[ Stage 2]

    Time frame: through study Stage2 completion,an average of 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2022; primary completion for Dec 2023, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
Jun 21, 2022
StartEst.
Jul 31, 2022
Primary completionEst.
Dec 30, 2023
CompletionEst.
Dec 30, 2024
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05425602
Lead sponsor
Maxinovel Pty., Ltd.
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jul 31, 2022 (estimated)
Primary completion
Dec 30, 2023 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jun 21, 2022

Study contacts

Ting Peng, MD,Ph.D
Contact
tpeng@maxinovel.com
13917659695
Zhengbo Song, MD,Ph.D
Contact
songzb@zjcc.org.cn
0571-88122168

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion